Korea's largest botulinum toxin (Botox-type) and filler maker, exporting aesthetic injectables to China, Europe and beyond.
Korea's largest botulinum toxin (Botox-type) and filler maker, exporting aesthetic injectables to China, Europe and beyond.
Sells its toxin and fillers to clinics, relying on distributors in each export market and on regulatory approvals country by country. Its toxin, also sold as Letybo, won US FDA approval in 2024, opening the largest aesthetics market. Exports are a large part of sales.
In one line: Korea's Allergan/Botox equivalent.
Moat: narrow (regulatory licence, brand). Regulatory-approved toxin strains and manufacturing scale are hard and costly to replicate.
Headquarters: Chuncheon, South Korea · Founded: 2001 · Employees: 629
Size Hugel (145020.KS) is a South Korea Health Care company (Biotechnology) with a market value of $1.69B, the 158th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩198,500 on 18 Nov 2026.
Performance Over six months the shares fell 30.5%, against 0.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 16.6% over the last twelve months (peer median +25.5%); the operating margin is 38.1% (peer median -0.2%).
Valuation It trades at 18.1× forward earnings against a peer median of 39.7× (3rd cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -27 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 17.5 points above its cost of capital (5.6% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩471B | ₩425B | ₩373B | ₩320B | ₩282B |
| Revenue growth | — | +14% | +17% | +13% | — |
| Gross profit | ₩354B | ₩323B | ₩278B | ₩238B | ₩211B |
| EBITDA | ₩202B | ₩220B | ₩181B | ₩132B | ₩115B |
| Net income | ₩125B | ₩141B | ₩136B | ₩93.1B | ₩60.7B |
| Free cash flow | ₩149B | ₩137B | ₩137B | ₩94.0B | ₩47.8B |
| Capital expenditure | ₩69.2B | ₩29.5B | ₩33.3B | ₩40.6B | ₩45.0B |
| Total debt | ₩25.7B | ₩29.1B | ₩37.6B | ₩90.5B | ₩101B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hugel 145020.KS | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% |
| Medy-Tox 086900.KS | $350M | -36% | +3% | 10% | 18.1× | 4.7% |
| Daewoong Pharm 069620.KS | $856M | -33% | +9% | 12% | 9.0× | n/a |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Ipsen IPN.PA | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 145020.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.8% | -7.8% | 4th highest of 20 |
| 6-month return | -30.5% | 0.0% | 3rd lowest of 20 |
| Distance from 52-week high | -35.7% | -36.1% | 10th highest of 21 |
| Revenue growth (TTM) | +16.6% | +25.5% | 7th lowest of 17 |
| Operating margin | 38.1% | -0.2% | 2nd highest of 18 |
| Forward P/E | 18.1× | 39.7× | 3rd cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -12.1% | 27.8% | least demanding of 5 |
| Growth delivered (Del g) | +15.0% | +20.8% | 2nd lowest of 5 |
| Hurdle (Req g minus delivered) | -27.1 pp | +12.3 pp | 2nd least demanding of 5 |
| ROIC minus cost of capital | +17.5 pp | -4.4 pp | highest of 13 |
| EV / EBITDA | 8.5× | 19.5× | 3rd cheapest of 6 |
| Net debt / EBITDA | -2.8× | 1.0× | 2nd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 52.1× | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 105.5× | 22.7% | +3.4% |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | n/a | n/a | n/a |